Sartorius’ Post

🔬 Thrilled to Present at SynBioBeta 2024! 🔬 Join Cedric Wu, VP of Innovation Center at GenScript USA Inc., on May 7th from 1:45 PM to 2:30 PM in the Grand Ballroom 220A for our session on "Accelerating Revolution in Biotech and BioPharma: The Power of Precision Mutant Libraries." 🧬 Discover the cutting-edge advancements in high-throughput DNA variant libraries that are reshaping protein engineering, target identification, and the development of gene and cell therapies. We'll explore how precision mutant DNA libraries, validated by deep learning models, are unlocking potential in areas like AAV capsids, enhancing tissue organ tropism, and CAR-T therapy design. 🌐 Whether you are involved in biopharma, bioengineering, or genomics, this session will provide a deep dive into the technologies driving rapid advancements in medical research and therapeutic development. Join us! https://lnkd.in/eWR-27hi #SynBioBeta2024 #Biopharma #GenScript #PrecisionHealth

Next week in Boston, Diego Cadavid, our CMO, will join Alexandra Snyder, MD, Najat Khan, PhD, Aparna S., and Rob Brown at Fierce Life Sciences Events' Biotech Summit for a panel that will uncover how #AI is revolutionizing drug discovery and development. Join us to hear how Verge uses human genomics from patient disease tissues and machine learning to develop therapeutics for complex diseases with high unmet need. #FierceBiotechSummit #Biotechnology

🚀 Exciting Announcement! 🚀 Introducing a game-changing method now available on the Biomek NGeniuS system! This cutting-edge technology automates library preparation for the Pillar Biosciences oncoReveal™ Solid Tumor 22 Gene Panel, revolutionizing NGS workflows. Highlights: 🧬 Automated library prep for solid tumor samples, including both genomic and FFPE DNA. ⏱️ Streamlines labor-intensive manual steps, enhancing efficiency and reducing errors. 📊 Delivers high-quality sequencing data with Q30 scores >97% and on-target rates >92%. 💡 Ensures reproducible results with accurate variant detection and zero false positives/negatives. This innovation promises to revolutionize your lab's workflow, enabling consistent and high-quality results with minimal operator input. Explore how the Biomek NGeniuS system can transform your sequencing processes! #NGS #Automation #Biotech #Innovation #LabEfficiency

In the dynamic world of Life Sciences, achieving precision, efficiency, and reliability is paramount. At InflexionPoint, we are proud to introduce you to Lab Owl v3.0 – our advanced bioreactor control system, designed to propel your research and production to new heights! 🌟 Lab Owl is not just a product; it’s a solution that understands and addresses the unique challenges of biotechnological processes. Whether you are in biotechnology, pharmaceuticals, cell and gene therapy, or cultured meat production, Lab Owl is tailored to enhance your operations: 🧪 Precision Control: Ensuring optimal conditions for every experiment and production run. 💡 Real-time Monitoring: Delivering insights as they happen, enabling informed decision-making. 🔄 Scalability: Adapting to your needs, whether you’re running a pilot study or scaling up production. At InflexionPoint, we believe in the transformative power of technology to shape the future of Life Sciences. Lab Owl is a testament to our commitment to innovation, quality, and our customers’ success. Join us on a journey to explore the potential of Lab Owl and discover how we can redefine the boundaries of what’s possible together! 🚀 Learn more: https://zurl.co/WJT6 #InflexionPoint #LabOwl #BioreactorControl #LifeSciences #Innovation

𝐓𝐚𝐢𝐥𝐨𝐫𝐞𝐝 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐟𝐨𝐫 𝐑𝐍𝐀 Transcriptomics is crucial for understanding the functional genome. Biogenity specializes in this domain, offering end-to-end solutions from sample preparation to sample analysis and data analysis. Our focus encompasses everything from mRNA to microRNAs, ensuring a comprehensive approach to studying various biological states and processes. This includes examining drug actions or identifying potential biomarkers. It's not just about data collection; we emphasize quality and interpretability, preparing presentation-ready results for your internal and external communications. Our high-throughput transcriptome solutions cater to both broad and specific research needs, detecting minute RNA inputs from diverse cells and tissues, starting at less than 500 pg. Embark on a journey of discovery with Biogenity's transcriptomics services. Visit us for more insights at https://lnkd.in/eZU-ayiT. #transcriptomics #omics #research #rna #lifescience #biotech

To develop and deploy advanced therapies at a commercial scale, the industry needs to start thinking like a manufacturing company... At the Alliance for Regenerative Medicine's Cell & Gene State of the Industry Briefing, Andrew Obenshain, CEO of Bluebird Bio joined Samarth Kulkarni, CEO of CRISPR Therapeutics and Gbola Amusa, MD, CFA, former CSO of Chardan on stage. Speaking on the challenges bluebird bio experienced in commercializing its advanced therapies, Andrew highlighted why a shift in focus is needed towards prioritizing manufacturing capabilities early: 🔎 Early and equal investment in tech solutions and scientific teams should be a priority 🔎 Embracing a manufacturer's mindset is important for long-term success 🔎 A proactive approach that advocates for a strong foundation in manufacturing will help ensure the delivery of life changing therapies to patients To enable scalable development and widespread patient access, manufacturing processes must be developed as early as when we are considering clinical efficacy and safety. It is imperative that we listen and learn from those who have walked this path before. Catch the full discussion: https://lnkd.in/gU_sJjg #manufacturingbrighterfutures #celltherapy #genetherapy #biotechnology #patientaccess

It was a pleasure discussing the overlap between drug discovery and cell therapy at the BioPharma Nexus Conference. In both cases, our goal is to manipulate the function of cells for therapeutic benefit, and many of the same AI/ML strategies that have proven success in one apply to the other. One approach I presented is sequential screening. Here, we test potential drug candidates in small, carefully chosen batches to minimize costs while still rapidly identifying promising targets. Models pre-trained on public perturbation data can be used to determine the most informative set of drugs to test at any given moment, thereby minimizing the number of total batches required. In this strategy, the AI assumes the role of scientific director, deciding which hypotheses to test and how to best allocate limited resources.

Finally, Pillar kit automated on Biomek NGeniuS !!

Happy July everyone, I hope we are all gearing up for some celebrations tomorrow 🎆 but in the mean time here is Biotech Company showcase #5 Gero 🌟 Gero is a preclinical-stage target & drug discovery company creating therapeutics for age-related diseases. Gero applies machine learning algorithms originating from the physics of complex systems to build clinically relevant disease progression models in real-world human data. Then we use molecular data such as Whole-Exome sequencing (or plasma proteomics) to RWD-based protective variants - therapeutic targets - potentially applicable to several indications simultaneously. The in-human drug discovery approach allows us to avoid the “preclinical trap” and select the most efficient targets against human (not mice) diseases. Gero has an active collaboration with Pfizer and their research has been published in Nature Communications and Science journals as well as covered by Scientific American and Popular Mechanics. ⭐ Whether you know Gero through their appearances at a conferences, their collaboration with Pfizer, multiple publications or even their shout out from the total 69 million follower social media pages Ladbible, Gero is becoming one of the best known names in the industry. We look forward to seeing you there Alexey Kadet #lsxusa #biotech #techbio #ai #investment #partnering

The proof is in the paper. More on our latest Nature Biotech paper, and the massive data reveal behind our lead AI drug for idiopathic pulmonary fibrosis for the promising TNIK target from Genetic Engineering & Biotechnology News. ◾ "For those who suspect that AI’s potential is understated, a piece of news has just appeared that will no doubt be taken as confirmation, however partial or contingent it may seem to AI’s doubters." ◾ "The paper, titled “A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models,” describes how scientists at Insilico Medicine and their collaborators leveraged predictive AI technology to bring a drug candidate for idiopathic pulmonary fibrosis (IPF) to the threshold of Phase II development." *Link to full story in comments #ai #genai #drugdiscovery #biotech #techbio #tnik #ipf #clinicaltrials